The achievement of genome-wide association studies (GWAS) has rapidly progressed our understanding of the etiology of coronary artery disease (CAD). It unlocks new strategies to strengthen the stalling of CAD drug development. In this review, we highlighted the recent drawbacks, mainly pointing out those involved in identifying causal genes and interpreting the connections between disease pathology and risk variants. We also benchmark the novel insights into the biological mechanism behind the disease primarily based on outcomes of GWAS. Furthermore, we also shed light on the successful discovery of novel treatment targets by introducing various layers of “omics” data and applying systems genetics strategies. Lastly, we discuss in-depth the significance of precision medicine that is helpful to improve through GWAS analysis in cardiovascular research.

全基因组关联研究（GWAS）的成就迅速增进了我们对冠状动脉疾病（CAD）病因学的理解。它开启了新的策略，以加强 CAD 药物开发的停滞。在这篇综述中，我们强调了最近的缺点，主要指出了那些涉及识别因果基因和解释疾病病理学与风险变异之间的联系的缺点。我们还主要根据 GWAS 的结果对疾病背后的生物学机制的新见解进行基准测试。此外，我们还通过引入不同层次的“组学”数据和应用系统遗传学策略，揭示了新治疗靶点的成功发现。最后，我们深入讨论了精准医学通过GWAS分析有助于提高心血管研究的意义。